Competitor Analysis: 2016 Update on Biosimilar & Biosuperior Therapeutic Antibodies - Research and Markets

Jun 08, 2016, 05:10 ET from Research and Markets

DUBLIN, June 8, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update"  report to their offering. 

     (Logo: )

This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. 

The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 - 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development. 

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). 

Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities. 

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab. 

Competitor projects are listed in a tabular format providing information on: 

- Drug Codes, 
- Target/Mechanism of Action, 
- Class of Compound, 
- Company, 
- Product Category, 
- Indication, 
- R&D Stage and 
- additional comments with a hyperlink leading to the source of information. 

Key Topics Covered: 

A) 2015 Sales of Therapeutic Antibodies 

B) Biosimilar and Biosuperior Anti-TNF Antibodies - 2016 Update 

1. Originator Anti-TNF Antibodies 

2. Biosuperior Anti-TNF Antibodies 

3. Biosimimilar Anti-TNF Antibodies 

C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies - 2016 Update 

1) Marketed Anti-VEGF/R Products in Oncology 

2) Anti-VEGF Biosuperiors of Avastin and Zaltrap 

3) Anti-VEGF-R Biosuperiors of Cyramza 

4) Avastin & Cyramza Biosimilar Pipeline in Oncology 

5) Marketed Anti-VEGF Products in Ophthalmology 

6) Anti-VEGF Biosuperiors of Lucentis and Eylea 

7) Other Anti-VEGF Molecules in Ophthalmology 

8) Lucentis Biosimilars in Ophthalmology 

9) Eylea Biosimilars in Ophthalmology 

10) Off-Label Use of Anti-VEGF in Ophthalmology 

D) Biosimilar and Biosuperior Anti-Her2 Antibodies - 2016 Update 

1. 2015 Anti-Her2 Antibody Sales 

2. Originator Anti-Her2 Antibodies 

3. Biosuperior Anti-Her2 Antibodies 

4. Biosimilar Anti-Her2 Antibodies 

5. Perjeta Biosimilar Antibodies 

E) Biosimilar and Biosuperior Anti-CD20 Antibodies - 2016 Update 

1. 2015 Sales of Anti-CD20 Antibodies 

2. Originator Anti-CD20 Antibodies 

3. Biosuperior Anti-CD20 Antibodies 

4. Biosimilar Anti-CD20 Antibodies 

5. Arzerra Biosimilar Antibodies 

F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update 

1. Sales of Anti-EGF-R Antibodies 

2. Originator Anti-EGF-R Antibodies 

3. Biosuperior Anti-EGF-R Antibodies 

4. Biosimilar Anti-EGF-R Antibodies 

G) Next Wave of Biosimilar Antibodies - 2016 Update 

H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines 

Companies Mentioned - Patial List

- 3SBio (Shenyang Sunshine Pharmaceutical Co) 
- AET Biotech 
- AREVA Med 
- AVEO Pharmaceuticals 
- AbClon 
- AbbVie 
- Ablynx 
- Affibody 
- Affilogic 
- Affimed Therapeutics 
- Affitech 
- Alvogen 
- Ambrx 
- Amega Biotech 
- Amgen 
- AngioChem 
- Apexigen 
- Aprogen 
- Archemix 
- Aryogen 
- Ascendis Pharma 
- AstraZeneca (MedImmune) 
- Avaxia Biologics 
- Axxo 
- Baliopharm 
- Baxalta 
- Bayer 
- biOasis Technologies 

For more information visit

Media Contact:
Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets